Gaine S, Sitbon O, Channick RN, et al. - Given that improved long-term outcomes in relation to early initiation of pulmonary arterial hypertension (PAH) therapies have been reported, yet there exist limited data on the early use of prostacyclin pathway agents, therefore, researchers assessed the prognostic worth of time from diagnosis as well as its influence on treatment response in post hoc analyses of GRIPHON which was the largest randomized controlled trial in PAH to date. They investigated how morbidity/mortality events and response to selexipag treatment in PAH could be impacted by time from diagnosis. In GRIPHON, a total of 1,156 patients suffering from PAH were randomized to selexipag or placebo. Cases were grouped post hoc into a time from diagnosis of ≤ 6 months and > 6 months at randomization. Findings revealed a worse prognosis of PAH patients who were newly diagnosed vs those with a longer time from diagnosis, in GRIPHON. More pronounced benefit of selexipag on disease progression was evident in patients treated earlier vs in those treated later.